ESTRO 2025 - Abstract Book

S1845

Clinical – Upper GI

ESTRO 2025

technology have enabled the delivery of high doses of highly focussed radiation utilising stereotactic body radiotherapy (SBRT) with potentially less side-effects. The aim of this systematic review is to review HRQOL outcomes in patients with painful PCa treated with SBRT and compare those managed with CPB. Material/Methods: MEDLINE, PubMed, EMBASE, Epub Ahead of Print, Cochrane Clinical Trials, Cochrane Systematic Review, Embase and PsycINFO databases were searched from inception to July 2024 using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses[2]. Studies including patients who received either SBRT or CPB for pain management related to PCa and reported HRQOL outcomes were eligible for review. Results: 42 studies underwent full text review, 11 met inclusion criteria; one single arm phase II SBRT study and seven randomised controlled trials of CPB versus placebo (two) or pharmacological therapy (two) or another method of CPB (two) and three prospective CPB studies. Eligible patients (n= 31) of the single included SBRT study had locally advanced PCa with predefined pain or abdominal discomfort according to the brief pain inventory (BPI). 40-42 Gray in –seven to ten fractions was delivered. 57% had a clinically significant reduction in pain and an improvement in HRQOL (global health quality of life mean change score 4.96) at four-weeks. CPB (11) studies included locally advanced PCa patients (n= 444) with increased pain scores predefined by the visual analogue scale or BPI. All patients who received CPB reported an improvement in pain scores at four to eight weeks. HRQOL measurement tools and timepoints varied across studies. EORTC QLQ-C30 was the most commonly used (N=5), SF-36 (1), FACT (3) and DDQ-15 (1). Overall, QOL improved in eight studies by four-weeks. One study described an initial improvement followed by deterioration after one-week and one study reported a deterioration at four-weeks. Conclusion: Dedicated studies of patients with predefined PCa associated pain receiving SBRT reporting HRQOL are lacking. In studies of CPB, HRQOL outcomes varied. Both SBRT and CPB appear to reduce pain in PCa and may be options for PCa associated pain management. Short to medium HRQOL benefit would be better assessed with a randomised controlled trial

Keywords: pancreas, SBRT, pain

References: Morganti, A.G., et al., Pain relief with short-term irradiation in locally advanced carcinoma of the pancreas. J Palliat Care, 2003. 19 (4): p. 258-62. 2. Page, M.J., et al., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, 2021. 372 : p. n71.

3830

Digital Poster Dosimetry comparison of 3DCRT and VMAT in Esophageal cancer treated with NeoadjuvantChemoRadiotherapy and correlation with postoperative complications

Pragna G S 1 , Jayashree N P 1 , Bramhiah Nallapati 1 , Santosh Kumar 1 , Shreekripa Rao 1 , Rechal Nisha Dsouza 1 , Sarath S Nair 1 , Jyothi Nagesh 1 , Shambhavi C 1 , Umesh Velu 1 , Anshul Singh 1 , Srinidhi G Chandraguthi 1 , Krishna Sharan 1 , Nawaz Usman 2 , Preethi Shetty 2 , Naveen Kumar 2 , Karthik S Udupa 3 , Ananth Pai 3 , Shirley Lewis Salins 1